Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL.

Autor: Sii S; Department of Urology, Austin Health, Melbourne, Victoria, Australia., Papa N; Department of Urology, Austin Health, Melbourne, Victoria, Australia., Yiu TW; Department of Urology, Austin Health, Melbourne, Victoria, Australia., Tempo J; Department of Urology, Austin Health, Melbourne, Victoria, Australia., Qu L; Department of Urology, Austin Health, Melbourne, Victoria, Australia., Perera M; Department of Urology, Austin Health, Melbourne, Victoria, Australia., Thompson I; Department of Urology, Health Science Centre at San Antonio, University of Texas, Austin, TX, USA., Ischia J; Department of Urology, Austin Health, Melbourne, Victoria, Australia.; Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia., Fleshner N; Division of Urology, University of Toronto, Toronto, Canada., Smith E; Maxwell Plus, Brisbane, Queensland, Australia., Ranasinghe W; Department of Urology, Monash Health, Melbourne, Victoria, Australia., Bolton D; Department of Urology, Austin Health, Melbourne, Victoria, Australia.; Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia., Woon DTS; Department of Urology, Austin Health, Melbourne, Victoria, Australia.; Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.

Publikováno v: BJU international [BJU Int] 2024 Nov 28. Date of Electronic Publication: 2024 Nov 28.

Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men.

Autor: Dong L; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Lajkosz K; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Sanchez-Salas R; Division of Urology, Department of Surgery, McGill University, Montreal, Quebec, Canada., Kuk C; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada.; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Canada., Xu W; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Tiwari RV; Department of Urology, Singapore General Hospital, Singapore.; Department of Urology, Sengkang General Hospital, Singapore., Dias Dos Santos CP; Department of Urology, L'Institut Mutualiste Montsouris, Paris, France., Qian H; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Wang J; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Dong B; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Pan J; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zhu Y; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Liu Q; Department of Pathology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Chan A; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada.; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Canada., Kwong JCC; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Woon DTS; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Nesbitt M; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Erlich A; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Canada., Kulkarni GS; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Perlis N; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Hamilton RJ; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Klotz L; Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Canada., Wallis CJD; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada.; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Canada., Nguyen DD; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada.; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Canada.; Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada., Macek P; Department of Urology, L'Institut Mutualiste Montsouris, Paris, France., Tay KJ; Department of Urology, Singapore General Hospital, Singapore., Huang H; Department of Urology, Singapore General Hospital, Singapore., Toi A; Department of Medical Imaging, University Health Network, Toronto, Canada., Finelli A; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Fleshner NE; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada., Cheng CWS; Department of Urology, Sengkang General Hospital, Singapore., Cathelineau X; Department of Urology, L'Institut Mutualiste Montsouris, Paris, France., van der Kwast TH; Department of Pathology, University Health Network, Toronto, Canada., Xue W; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zlotta AR; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Canada.; Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Canada.

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Nov 15; Vol. 22 (10). Date of Electronic Publication: 2024 Nov 15.

Predicting Biochemical Recurrence of Prostate Cancer Post-Prostatectomy Using Artificial Intelligence: A Systematic Review.

Autor: Liu J; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne 3002, Australia.; Department of Urology, The Royal Melbourne Hospital, The University of Melbourne, Melbourne 3052, Australia.; Department of Surgery, The University of Melbourne, Melbourne 3052, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3051, Australia., Zhang H; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne 3002, Australia.; Department of Surgery, The University of Melbourne, Melbourne 3052, Australia., Woon DTS; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne 3002, Australia.; Department of Surgery, The University of Melbourne, Melbourne 3052, Australia., Perera M; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne 3002, Australia.; Department of Surgery, The University of Melbourne, Melbourne 3052, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3051, Australia., Lawrentschuk N; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne 3002, Australia.; Department of Urology, The Royal Melbourne Hospital, The University of Melbourne, Melbourne 3052, Australia.; Department of Surgery, The University of Melbourne, Melbourne 3052, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3051, Australia.

Publikováno v: Cancers [Cancers (Basel)] 2024 Oct 25; Vol. 16 (21). Date of Electronic Publication: 2024 Oct 25.

A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans.

Autor: Liu J; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3005, Australia.; Department of Urology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC 3052, Australia.; Department of Surgery, University of Melbourne, Melbourne, VIC 3052, Australia., Cundy TP; Discipline of Surgery, University of Adelaide, Adelaide, SA 5005, Australia., Woon DTS; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3005, Australia.; Department of Surgery, University of Melbourne, Melbourne, VIC 3052, Australia., Lawrentschuk N; E.J. Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, VIC 3005, Australia.; Department of Urology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC 3052, Australia.; Department of Surgery, University of Melbourne, Melbourne, VIC 3052, Australia.

Publikováno v: Cancers [Cancers (Basel)] 2024 Jan 23; Vol. 16 (3). Date of Electronic Publication: 2024 Jan 23.

A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide.

Autor: Woon DTS; Division of Urology, University Health Network, University of Toronto., Finelli A; Division of Urology, University Health Network, University of Toronto., Cheung DC; Division of Urology, University Health Network, University of Toronto., Martin LJ; Division of Urology, University Health Network, University of Toronto., Alibhai S; Department of Medicine, University Health Network, University of Toronto., Wallis CJD; Division of Urology, University Health Network, University of Toronto; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville., Diong C; ICES, Toronto, Canada., Saskin R; ICES, Toronto, Canada., Kulkarni G; Division of Urology, University Health Network, University of Toronto., Fleshner N; Division of Urology, University Health Network, University of Toronto. Electronic address: neil.fleshner@uhn.ca.

Publikováno v: Urology [Urology] 2021 Jul; Vol. 153, pp. 147-155. Date of Electronic Publication: 2021 Feb 13.